Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK.
Phospholipid scramblase 1 (PLSCR1), a calcium-binding protein that either inserts into the plasma membrane or binds to genomic DNA in the nucleus, has been shown to contribute to the cell proliferation, differentiation, and apoptosis as well as antiviral activity of interferon (IFN). The expression of PLSCR1 protein is also known to be markedly increased in response to IFN and to some differentiation inducing agents such as all-trans retinoic acid, but the precise mechanisms of this response remain to be investigated. In this study, we show that the protein kinase Cdelta (PKCdelta)-specific inhibitor rottlerin and the dominant negative mutant of PKCdelta significantly antagonized IFN-induced PLSCR1 expression. The influence of PKCdelta on IFN-mediated induction of PLSCR1 was dependent upon the phosphorylation of STAT1 at Ser-727. Furthermore, PKCdelta-mediated activation of STAT1 required the activation of JNK, as the inhibition of JNK activity by its specific inhibitor or transfection of its dominant negative mutant suppressed both serine phosphorylation of STAT1 and PLSCR1 expression but not the activation of PKCdelta. In conclusion, our results suggest that the induction of PLSCR1 transcription through STAT1 depends upon sequential activation of PKCdelta and JNK.
Zhao
Ke-Wen
KW
Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis, Chinese Ministry of Education, Rui-Jin Hospital, Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), Shanghai 200025, China.
Li
Dong
D
Zhao
Qian
Q
Huang
Ying
Y
Silverman
Robert H
RH
Sims
Peter J
PJ
Chen
Guo-Qiang
GQ
D000098:Acetophenones / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology; D015153:Blotting, Western; D002454:Cell Differentiation; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation; D004247:DNA / Q000378:metabolism; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic; D005799:Genes, Dominant; D006801:Humans; D016898:Interferon-alpha / Q000378:metabolism*; D007372:Interferons / Q000378:metabolism; D007700:Kinetics; D048670:MAP Kinase Kinase 4 / Q000378:metabolism*; D049294:Phospholipid Transfer Proteins / Q000096:biosynthesis*; D010766:Phosphorylation; D010957:Plasmids / Q000378:metabolism; D051745:Protein Kinase C-delta / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050794:STAT1 Transcription Factor / Q000378:metabolism*; D012694:Serine / Q000737:chemistry; D014158:Transcription, Genetic; D015533:Transcriptional Activation; D014162:Transfection; D014212:Tretinoin / Q000378:metabolism; D020298:U937 Cells; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D000098:Acetophenones; D001578:Benzopyrans; D004791:Enzyme Inhibitors; D016898:Interferon-alpha; C493422:PLSCR1 protein, human; D049294:Phospholipid Transfer Proteins; D012333:RNA, Messenger; D050794:STAT1 Transcription Factor; D012694:Serine; D014212:Tretinoin; D004247:DNA; D007372:Interferons; C085746:rottlerin; D051745:Protein Kinase C-delta; D048051:p38 Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4